ProCE Banner Activity

Low-Dose Hypomethylating Agents Active, Safe in Low- and Intermediate-1–Risk MDS

Slideset Download
Conference Coverage
ORR 60% among patients with lower-risk MDS treated with low-dose azacitidine or decitabine.

Released: December 06, 2016

Expiration: December 05, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen